Eosinophilic Airway Inflammation in Patients with Stable Biomass Smoke- versus Tobacco Smoke-Associated Chronic Obstructive Pulmonary Disease.
COPD
biomass smoke
chronic obstructive pulmonary disease
eosinophils
inflammation
pathogenesis
small airway
Journal
Journal of health & pollution
ISSN: 2156-9614
Titre abrégé: J Health Pollut
Pays: United States
ID NLM: 101690849
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
23
06
2019
accepted:
30
09
2019
entrez:
2
1
2020
pubmed:
2
1
2020
medline:
2
1
2020
Statut:
epublish
Résumé
Chronic obstructive pulmonary disease (COPD) is an inflammatory disease with predominant involvement of neutrophils, macrophages and CD8+ lymphocytes. Eosinophilic airway inflammations are reported in stable state and during acute exacerbations of tobacco smoke-associated COPD (TS-COPD). Women exposed to biomass fuel smoke are known to have eosinophils in sputum. However, little is known about the sputum cellular inflammatory profile in biomass fuel smoke-associated COPD (BMS-COPD). We therefore aimed to compare the sputum cellular inflammatory profile in tobacco smoke- and biomass smoke-associated COPD. The study was conducted in a tertiary care hospital in Goa, India. A total of 113 patients with stable COPD reporting to the outpatient pulmonary clinic were recruited. All participants were ≥ 40 years of age. Sputum induction studies were performed by the method of Pizzichini There were 85 TS-COPD and 28 BMS-COPD patients. The mean age [standard deviation (SD)] was 64.7 (7.8) and 63.0 years (8.3), p = 0.32 in TS and BMS-COPD, respectively. Eighteen subjects (21.1%) were female smokers. The smoking pack-year median [interquartile range (IQR)] was 36 (20, 58) and hour-years of biomass smoke exposure mean (SD) was 192.4 (61). The TS-COPD and BMS-COPD cases showed a post-bronchodilator forced expiratory volume in one second (FEV1%) mean (SD) of 57.9 (17.1), and 62.6 (19.4), p= 0.22, respectively. Both groups had similar symptoms and severity of disease. Induced sputum total cell count per gram of sputum × 10 For similar severity of disease and clinical symptoms, significant eosinophilic inflammation was observed in stable BMS-COPD, while both groups had similar neutrophilic inflammation. Obtained. The study was approved by the Institutional Ethics Committee of the Goa Medical College, Goa, India. The authors declare no competing financial interests.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic obstructive pulmonary disease (COPD) is an inflammatory disease with predominant involvement of neutrophils, macrophages and CD8+ lymphocytes. Eosinophilic airway inflammations are reported in stable state and during acute exacerbations of tobacco smoke-associated COPD (TS-COPD). Women exposed to biomass fuel smoke are known to have eosinophils in sputum. However, little is known about the sputum cellular inflammatory profile in biomass fuel smoke-associated COPD (BMS-COPD). We therefore aimed to compare the sputum cellular inflammatory profile in tobacco smoke- and biomass smoke-associated COPD.
METHODS
METHODS
The study was conducted in a tertiary care hospital in Goa, India. A total of 113 patients with stable COPD reporting to the outpatient pulmonary clinic were recruited. All participants were ≥ 40 years of age. Sputum induction studies were performed by the method of Pizzichini
RESULTS
RESULTS
There were 85 TS-COPD and 28 BMS-COPD patients. The mean age [standard deviation (SD)] was 64.7 (7.8) and 63.0 years (8.3), p = 0.32 in TS and BMS-COPD, respectively. Eighteen subjects (21.1%) were female smokers. The smoking pack-year median [interquartile range (IQR)] was 36 (20, 58) and hour-years of biomass smoke exposure mean (SD) was 192.4 (61). The TS-COPD and BMS-COPD cases showed a post-bronchodilator forced expiratory volume in one second (FEV1%) mean (SD) of 57.9 (17.1), and 62.6 (19.4), p= 0.22, respectively. Both groups had similar symptoms and severity of disease. Induced sputum total cell count per gram of sputum × 10
CONCLUSIONS
CONCLUSIONS
For similar severity of disease and clinical symptoms, significant eosinophilic inflammation was observed in stable BMS-COPD, while both groups had similar neutrophilic inflammation.
PARTICIPANT CONSENT
UNASSIGNED
Obtained.
ETHICS APPROVAL
UNASSIGNED
The study was approved by the Institutional Ethics Committee of the Goa Medical College, Goa, India.
COMPETING INTERESTS
UNASSIGNED
The authors declare no competing financial interests.
Identifiants
pubmed: 31893170
doi: 10.5696/2156-9614-9.24.191209
pmc: PMC6905135
doi:
Types de publication
Journal Article
Langues
eng
Pagination
191209Informations de copyright
© Pure Earth 2019.
Références
ERJ Open Res. 2017 Apr 12;3(2):null
pubmed: 28828380
Chest. 2010 Jul;138(1):3-6
pubmed: 20605806
Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65
pubmed: 22878278
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
Int J Hyg Environ Health. 2013 Jun;216(3):301-8
pubmed: 22771078
Int J Chron Obstruct Pulmon Dis. 2015 Jun 09;10:1075-83
pubmed: 26089657
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Am J Respir Crit Care Med. 2011 Sep 15;184(6):662-71
pubmed: 21680942
Eur Respir J. 2014 Mar;43(3):725-34
pubmed: 24114962
Inflammation. 2012 Apr;35(2):671-83
pubmed: 21769440
Lancet. 2000 Oct 28;356(9240):1480-5
pubmed: 11081531
Innate Immun. 2016 Jul;22(5):373-81
pubmed: 27226464
Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):308-17
pubmed: 8756799
Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1511-7
pubmed: 9817701
COPD. 2005 Jun;2(2):277-83
pubmed: 17136954
Exp Lung Res. 2013 Aug;39(6):229-40
pubmed: 23682816
Respiration. 2012;83(1):36-44
pubmed: 21912093
Eur Respir J. 2014 Dec;44(6):1697-700
pubmed: 25323230
Am J Respir Crit Care Med. 2008 Jan 1;177(1):19-26
pubmed: 17916806
Eur Respir J. 2017 Oct 12;50(4):
pubmed: 29025891
Chest. 2003 Apr;123(4):1054-9
pubmed: 12684293
J Allergy Clin Immunol. 2017 Oct;140(4):1181-1184.e7
pubmed: 28506852
Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1646-52
pubmed: 7952628
Clinics (Sao Paulo). 2011;66(6):1081-7
pubmed: 21808879
Nat Rev Immunol. 2002 May;2(5):372-7
pubmed: 12033743
Eur Respir J. 2006 May;27(5):964-71
pubmed: 16446316
Thorax. 2005 Mar;60(3):193-8
pubmed: 15741434
Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):475-8
pubmed: 10673188
Am J Respir Crit Care Med. 2015 Aug 15;192(4):523-5
pubmed: 26051430
Lancet. 2011 Sep 10;378(9795):1015-26
pubmed: 21907865
Nat Rev Immunol. 2008 Mar;8(3):183-92
pubmed: 18274560